Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection

Transplant International

Volumn 25, Issue 9, 2012, Pages 925-934

  Hirai, Toshihito ^a,b   Kohei, Naoki ^a   Omoto, Kazuya ^a   Ishida, Hideki ^a   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

antibody mediated rejection; donor specific antibody; rituximab

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; B LYMPHOCYTE; CHRONIC GRAFT REJECTION; CYTOTOXICITY; DESENSITIZATION; DOULBLE FILTRATION PLASMAPHERESIS; FEMALE; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SURVIVAL RATE; T LYMPHOCYTE;

ABO BLOOD-GROUP SYSTEM; ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS; BIOPSY; CHRONIC DISEASE; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; RETROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84864689465     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01518.x     Document Type: Article

References (41)

1. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
2. Amico P, Hirt-Minkowski P, Hönger G, et al. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transpl Int 2011; 24: 560.
3. Patel AM, Pancoska C, Mulgaonkar S, Weng FL,. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371.
4. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
5. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70: 589.
6. Gupta A, Sinnott P,. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: A risk factor. Hum Immunol 2009; 70: 618.
7. Kwun J, Knechtle SJ,. Overcoming chronic rejection-can it B? Transplantation 2009; 88: 955.
8. Zhang X, Reed EF,. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459.
9. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832.
10. Ishida H, Tanabe K, Furusawa M, et al. Evaluation of flow cytometric panel reactive antibody in renal transplant recipients-examination of 238 cases of renal transplantation. Transpl Int 2005; 18: 163.
11. Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9: 567.
12. Hirai T, Ishida H, Toki D, et al. Comparison of the acute rejection incidence rate in spousal donor transplantation before and after anti-CD20 antibody (rituximab) protocol as desensitization therapy. Ther Apher Dial. 2011; 15: 89.
13. Preiksaitis JK, Brennan DC, Fishman J, Allen U,. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
14. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K,. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469.
15. Lefaucheur C, Antoine C, Suberbielle C, Glotz D,. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11: 1592.
16. Tongio MM, Falkenrodt A, Mitsuishi Y, et al. Natural HLA antibodies. Tissue Antigens 1985; 26: 271.
17. El-Awar N, Terasaki PI, Nguyen A, et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009; 70: 844.
18. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J,. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111.
19. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982.
20. Ishida H, Hirai T, Kohei N, Yamaguchi Y, Tanabe K,. Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation. Transpl Int 2011; 24: 150.
21. Bartel G, Schwaiger E, Böhmig GA,. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011; 24: 1142.
22. Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO,. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transplant Infectious Disease 2010; 12: 473.
23. Lee MY, Chiou TJ, Hsiao LT, et al. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 2008; 87: 285.
24. Suzan F, Ammor M, Ribrag V,. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
25. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
26. Jordan SC, Glotz D,. Is rituximab safe to use in kidney transplant patients? Am J Transplant 2010; 10: 8.
27. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
28. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K,. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010; 89: 1466.
29. Tydén G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
30. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1. Transplantation 2004; 77: 542.
31. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
32. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
33. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K,. Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transpl Immunol 2010; 23: 220.
34. Stegall MD, Gloor J, Winters JL, Moore SB, DeGoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
35. Terasaki PI, Cai J,. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86: 377.
36. Ozawa M, Rebellato L, Terasaki P, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transpl 2006; 265.
37. van Vollenhoven RF, Emery P, Bingham CO, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. The Journal of rheumatology 2010; 37: 558.
38. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
39. Liu C, Noorchashm H, Sutter JA, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007; 13: 1295.
40. + B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation 2009; 87: 1394.
41. Biglarnia A-R, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011; 24: e61.